Nonalcoholic fatty liver disease is associated with lower hepatic and erythrocyte ratios of phosphatidylcholine to phosphatidylethanolamine

被引:111
作者
Arendt, Bianca M. [1 ]
Ma, David W. L. [2 ]
Simons, Brigitte [3 ]
Noureldin, Seham A. [1 ]
Therapondos, George [1 ]
Guindi, Maha [1 ]
Sherman, Morris [1 ]
Allard, Johane P. [1 ]
机构
[1] Univ Hlth Network, Dept Med, Toronto, ON M5G 2C4, Canada
[2] Univ Guelph, Dept Human Hlth & Nutr Sci, Guelph, ON N1G 2W1, Canada
[3] AB SCIEX, Concord, ON L4K 4V8, Canada
来源
APPLIED PHYSIOLOGY NUTRITION AND METABOLISM-PHYSIOLOGIE APPLIQUEE NUTRITION ET METABOLISME | 2013年 / 38卷 / 03期
基金
加拿大健康研究院;
关键词
nonalcoholic fatty liver disease; steatohepatitis; phosphatidylcholine; phosphatidylethanolamine; lipid composition; healthy controls; mass spectrometry; TREATMENT PANEL-III; CHOLINE; STEATOHEPATITIS; SUSCEPTIBILITY; BETAINE; GENE; POLYMORPHISM; REQUIREMENT; HOMEOSTASIS; MEMBRANE;
D O I
10.1139/apnm-2012-0261
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Nonalcoholic fatty liver disease (NAFLD) is associated with altered hepatic lipid composition. Animal studies suggest that the hepatic ratio of phosphatidylcholine (PC) to phosphatidylethanolamine (PE) contributes to steatogenesis and inflammation. This ratio may be influenced by dysregulation of the PE N-methyltransferase (PEMT) pathway or by a low-choline diet. Alterations in the liver may also influence lipid composition in circulation such as in erythrocytes, which therefore may have utility as a biomarker of hepatic disease. Currently, no study has assessed both liver and erythrocyte PC/PE ratios in NAFLD. The aim of this study was to compare the PC/PE ratio in the liver and erythrocytes of patients with simple steatosis (SS) or nonalcoholic steatohepatitis (NASH) with that of healthy controls. PC and PE were measured by mass spectrometry in 28 patients with biopsy-proven NAFLD (14 SS, 14 NASH) and 9 healthy living liver donors as controls. The hepatic PC/PE ratio was lower in SS patients (median [range]) (1.23 [0.27-3.40]) and NASH patients (1.29 [0.77-3.22]) compared with controls (3.14 [2.20-3.73]); both p < 0.001) but it was not different between SS and NASH. PC was lower and PE higher in the liver of SS patients compared with controls, whereas in NASH patients only PE was higher. The PC/PE ratio in erythrocytes was also lower in SS and NASH patients compared with controls because of lower PC in both patient groups. PE in erythrocytes was not different among the groups. In conclusion, NAFLD patients have a lower PC/PE ratio in the liver and erythrocytes than do healthy controls, which may play a role in the pathogenesis. The underlying mechanisms require further investigation.
引用
收藏
页码:334 / 340
页数:7
相关论文
共 37 条
  • [1] Betaine for Nonalcoholic Fatty Liver Disease: Results of a Randomized Placebo-Controlled Trial
    Abdelmalek, Manal F.
    Sanderson, Schuyler O.
    Angulo, Paul
    Soldevila-Pico, Consuelo
    Liu, Chen
    Peter, Joy
    Keach, Jill
    Cave, Matt
    Chen, Theresa
    McClain, Craig J.
    Lindor, Keith D.
    [J]. HEPATOLOGY, 2009, 50 (06) : 1818 - 1826
  • [2] The role of the gut microbiota in nonalcoholic fatty liver disease
    Abu-Shanab, Ahmed
    Quigley, Eamonn M. M.
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2010, 7 (12) : 691 - 701
  • [3] Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): A cross-sectional study
    Allard, Johane P.
    Aghdassi, Elaheh
    Mohammed, Saira
    Raman, Maitreyi
    Avand, Ghazal
    Arendt, Bianca M.
    Jalali, Pegah
    Kandasamy, Thileep
    Prayitno, Nita
    Sherman, Morris
    Guindi, Maha
    Ma, David W. L.
    Heathcote, Jenny E.
    [J]. JOURNAL OF HEPATOLOGY, 2008, 48 (02) : 300 - 307
  • [4] Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatiosis in patients with non-alcoholic fatty liver disease
    Araya, J
    Rodrigo, R
    Videla, LA
    Thielemann, L
    Orellana, M
    Pettinelli, P
    Poniachik, J
    [J]. CLINICAL SCIENCE, 2004, 106 (06) : 635 - 643
  • [5] Brunt EM, 1999, AM J GASTROENTEROL, V94, P2467, DOI 10.1111/j.1572-0241.1999.01377.x
  • [6] Choline deficiency causes reversible hepatic abnormalities in patients receiving parenteral nutrition: Proof of a human choline requirement: A placebo-controlled trial
    Buchman, AL
    Ament, ME
    Sohel, M
    Dubin, M
    Jenden, DJ
    Roch, M
    Pownall, H
    Farley, W
    Awal, M
    Ahn, C
    [J]. JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, 2001, 25 (05) : 260 - 268
  • [7] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [8] Phosphatidylcholine and cell death
    Cui, Z
    Houweling, M
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2002, 1585 (2-3): : 87 - 96
  • [9] Common genetic polymorphisms affect the human requirement for the nutrient choline
    da Costa, Kerry-Ann
    Kozyreva, Olga G.
    Song, Jiannan
    Galanko, Joseph A.
    Fischer, Leslie M.
    Zeisel, Steven H.
    [J]. FASEB JOURNAL, 2006, 20 (09) : 1336 - 1344
  • [10] Daly AK, 2011, EXPERT REV GASTROENT, V5, P253, DOI [10.1586/EGH.11.18, 10.1586/egh.11.18]